Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM Raises $37 Million in Private Placement
ZIOPHARM Raises $37 Million in Private Placement NEW YORK, NY - May 3, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today it has completed a private placement of approximately 8.0 million shares of its common stock with gross proceeds of approximately $37.0 million.
View HTML
Toggle Summary ZIOPHARM Announces 2006 Annual Meeting of Stockholders
ZIOPHARM Announces 2006 Annual Meeting of Stockholders NEW YORK, NY - April 20, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today it will hold its Annual Meeting of Stockholders on Wednesday, April 26, 2006 at 10:00 a.m. EST at the New York Academy of Science.
View HTML
Toggle Summary ZIOPHARM to Present at BIO 2006 in Chicago
ZIOPHARM to Present at BIO 2006 in Chicago NEW YORK, NY - April 6, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today Dr. Jonathan Lewis, Chief Executive Officer, will present at the BIO 2006 Annual International Convention on Tuesday, April 11, 2006 at 9:30 a.m. CDT (10:30 a.m.
View HTML
Toggle Summary ZIOPHARM Announces ZIO-101 Anti-Cancer Activity at AACR
-- Mechanism and Toxicity Profile of Arsenic Important in Treating Myeloma --
View HTML
Toggle Summary ZIOPHARM Presents ZIO-201/202/203 Preclinical Data at AACR
-- Anti-Cancer Activity in Leukemia, Pancreas, and Prostate Cancers --
View HTML
Toggle Summary ZIOPHARM Reports 2005 Year End Financial Results and Accomplishments
- Expect significant newsflow in 2006 -
View HTML
Toggle Summary ZIOPHARM to Present at BioSquare 2006 in Geneva
ZIOPHARM to Present at BioSquare 2006 in Geneva NEW YORK, NY - March 2, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Barbara Wallner, Ph.D., Senior Vice President, Technical Operations and Chief Technical Officer, will present at BioSquare 2006 on Thursday, March 9, 2006 at
View HTML
Toggle Summary ZIOPHARM Treats First Patient in ZIO-201 Phase I/II in Sarcoma
-- Clinical Development Plan on Track --
View HTML
Toggle Summary ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone Marrow Transplant Meetings
ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone Marrow Transplant Meetings NEW YORK, NY - February 21, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal kidney cells
View HTML
Toggle Summary ZIOPHARM Presents ZIO-201 Preclinical Data at Bone Marrow Transplant Meetings
ZIOPHARM Presents ZIO-201 Preclinical Data at Bone Marrow Transplant Meetings NEW YORK, NY - February 17, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data today at the 2006 Bone Marrow Transplant Meetings in Honolulu demonstrating that ZIO-201, the Company's proprietary
View HTML